3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| AMZL, LPFiled to raise in 2023, with no closing reported yet. | 2023 | Indefinite | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Matthew Foy | Quiet | Biotech & pharma | 2 | 0 |
Classified sectors of Amzl’s own portfolio companies, based on 20 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Amzl’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Synapse Investment | 19 | ADARx Pharmaceuticals, Adheron Therapeutics, ARS Pharmaceuticals, Auxogyn, Avenzo Therapeutics, Avhana Health, CRISPR Therapeutics AG, Dren Bio, EFFECTOR THERAPEUTICS, FORE US Bio, HTG MOLECULAR DIAGNOSTICS, IlluminOss Medical, Navitor Pharmaceuticals, Palleon Pharmaceuticals, Principia Biopharma, Rezo Therapeutics, RUIYI, Simcha Therapeutics Holding Company, TP Therapeutics |
| Orbimed Israel Partners | 5 | ADARx Pharmaceuticals, Atox Bio, Avenzo Therapeutics, FORE US Bio, TP Therapeutics |
| Orbimed Genesis | 4 |
| Rajeev Dadoo | Quiet | Biotech & pharma, Digital health, Medical devices | 8 | 0 |
| Simeon George | Quiet | Biotech & pharma, Medical devices | 11 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| ADARx Pharmaceuticals, Avenzo Therapeutics, Principia Biopharma, TP Therapeutics |
| Orbimed New Horizons | 4 | ADARx Pharmaceuticals, Avenzo Therapeutics, Principia Biopharma, TP Therapeutics |
| Orbimed Partners | 4 | ADARx Pharmaceuticals, Avenzo Therapeutics, Principia Biopharma, TP Therapeutics |
| Orbimed Private Investments | 4 | ADARx Pharmaceuticals, Avenzo Therapeutics, Principia Biopharma, TP Therapeutics |
| Caduceus Capital | 3 | ADARx Pharmaceuticals, Avenzo Therapeutics, TP Therapeutics |
| Orbimed Asia Partners | 3 | ADARx Pharmaceuticals, Avenzo Therapeutics, TP Therapeutics |
| Orbimed Global Healthcare | 3 | ADARx Pharmaceuticals, Avenzo Therapeutics, TP Therapeutics |
| Vivo Capital | 2 | ADARx Pharmaceuticals, TP Therapeutics |
| Abingworth Bioventures | 1 | EFFECTOR THERAPEUTICS |
| Atlas Venture | 1 | Navitor Pharmaceuticals |
| Bain Capital Life Sciences | 1 | ADARx Pharmaceuticals |
| Pivotal bioVenture Partners | 1 | HTG MOLECULAR DIAGNOSTICS |
| Sofinnova Venture Partners | 1 | EFFECTOR THERAPEUTICS |
A shared board seat: a company where filings name a Amzl partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
